newsfilter
← Latest News
GlobeNewswire·

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (NASDAQ:PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical